Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode

General Hospital Psychiatry

Volumn 28, Issue 1, 2006, Pages 59-64

  Pintor, Luis ^a   Baillès, Eva ^a   Valldeoriola, Francesc ^a   Tolosa, Eduard ^a   Martí, María J ^a   De Pablo, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Depression; Parkinson's disease; Reboxetine; Response

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT; REBOXETINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; RASH; REMISSION; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWEATING; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; URINE RETENTION; VERTIGO; XEROSTOMIA;

AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MORPHOLINES; PARKINSON DISEASE; PILOT PROJECTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 29244439926     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2005.07.005     Document Type: Article

References (28)

1. E. Tandberg, J.P. Larsen, D. Aarsland, and J.L. Cummings The occurrence of depression in Parkinson's disease: a community-based study Arch Neurol 53 1996 175 179
2. T. Tom, and J.L. Cummings Depression in Parkinson's disease: pharmacological characteristics and treatment Drugs Aging 12 1998 55 74
3. T. Klaasen, F.R.J. Verhey, G.H.J.M. Sneijders, N. Rozendaal, and H.V.W. Vet Treatment of depression in Parkinson's disease: a meta-analysis J Neuropsychiatry Clin Neurosci 7 1995 281 286
4. J. Andersen, E. Aabro, N. Gulmann, and H.E. Pedersen Antidepressive treatment in Parkinson's disease - a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with l-DOPA Acta Neurol Scand 62 1980 210 219
5. L. Wermouth, P.S. Sorensen, B. Timm, N.P. Utzon, and J. Boas Depression in idiopathic Parkinson's disease treated with citalopram - a placebo-controlled trial Nord J Psychiatry 52 1998 163 169
6. J.M. Rabey, E. Orlov, and A.D. Korczyn Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease Neurology 46 1996 374
7. J.P. Feighner Mechanism of action of antidepressant medications Review J Clin Psychiatry 60 4, Suppl 1999 4 11
8. G. Dell'Agnello, R. Ceravolo, A. Nuti, G. Bellini, A. Piccini, and C. D'Avino SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study Clin Neuropharmacol 24 4 2001 221 227
9. H. Allain, S. Schuck, and N. Maudit Depression in Parkinson's disease (editorial) BMJ 320 2000 1287 1288
10. S.A. Montgomery Reboxetine: additional benefits to the depressed patient J Psychopharmacol 11 4, Suppl 1997 9 15
11. G.D. Burrows, K.P. Maguire, and T.R. Norman Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review J Clin Psychiatry 59 14, Suppl 1998 4 7
12. M.R. Lemke Effect of reboxetine on depression in Parkinson's disease patients J Clin Psychiatry 63 2002 300 304
13. A.J. Hughes, S.E. Daniel, L. Kilford, and A.J. Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 1992 181 184
14. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset progression and mortality Neurology 17 1967 427 442
15. S. Fahn, R.L. Elton, and Members of the UPDRS Development Committee Unified Parkinson disease rating scale (UPDRS) S. Fahn C.D. Marsden D.B. Calne Recent developments in Parkinson's disease vol. 2 1987 Macmillan New York (NY) 153 164
16. American Psychiatry Association Diagnostic and statistical manual of mental disorders 4th ed. 1994 American Psychiatry Association Washington
17. M.B. First, R.L. Spitzer, M. Gibbon, and J.B.W. Williams Structured Clinical Interview for DSM-IV axis I disorders - clinician version (SCID-CV) 1997 American Psychiatry Association Press, Inc Washington (DC) [versión española, S.A. Masson, 1999]
18. J.A. Yesavage, T.L. Brink, T.L. Rose, O. Lum, and V. Huang Development and validation of a geriatric depression screening scale: a preliminary report J Psychiatr Res 17 1982-83 37 49
19. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
20. M.J. Herrero, X. Torres, J. Blanch, J.M. Peri, and L. Pintor A validation study of the Hospital anxiety and depression scale (HADS) in a Spanish population Gen Hosp Psychiatry 25 2003 277 283
21. J. Alonso, L. Prieto, and J.M. Antó The Spanish version of the Nottingham Health Profile: a review of adaptation and instrument characteristics Qual Life Res 3 1994 385 393
22. E. Frank, R.F. Prien, R.B. Jarret, M.B. Keller, and D.J. Kupfer Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence Arch Gen Psychiatry 48 1991 851 855
23. R. Sandyk Hypothalamic-locus coeruleus mechanisms in the pathophysiology of "on-off" in l-dopa treated Parkinson's disease: a hypothesis Int J Neurosci 47 1989 303 308
24. H. Narabayashi Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease Adv Neurol 80 1999 501 504
25. M. Mucci Reboxetine: a review of antidepressant tolerability J Psychopharmacol 11 1, Suppl 1997 33 37
26. M. Versiani, L. Mehilane, P. Gaszner, and R. Arnaud-Castiglioni Reboxetine, a unique selective NRI, prevents relapse and recurrence in long term treatment of major depressive disorder J Clin Psychiatry 60 1999 400 406
27. S. Yosselson-Superstine, and A.G. Lipman Chlordiazepoxide interaction with levodopa Ann Intern Med 96 2 1982 259 260
28. Z. Rogoz, W. Margas, G. Skuza, J. Solich, M. Kusmider, and M. Dziedzicka-Wasylewska Effect of repeated treatment with reboxetine on central alpha 1-adrenergic and dopaminergic receptors Pol J Pharmacol 54 6 2002 593 603